Galmed Pharmaceuticals Ltd.
GLMD
|
$0.3614
11K
|
Health Technology
(0.0% 1d) (12.4% 1m) (-99.5% 1y) (0.0% 2d) (0.0% 3d) (-2.7% 7d) (3.2% volume)
Earnings Calendar: 2022-11-07
Market Cap: $ 1,823,380
http://www.galmedpharma.com
Sec Filling | Patents | 21 employees
(IL) Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
diabetes diabetic israel hepatitis nash treatment
add to watch list Paper trade email alert is off
Press-releases
Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Published: 2024-04-04 (Crawled : 21:00) - prnewswire.com
GLMD | $0.3614 11K
|
Health Technology
|
| O: -2.42%
H: 5.59%
C: 5.59%
report year pharmaceuticals for
Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis
Published: 2024-03-15 (Crawled : 13:00) - prnewswire.com
GLMD | $0.3614 11K
|
Health Technology
|
| O: 17.48%
H: 0.0%
C: -25.59%
mgl-3196 patent liver treatment fibrosis grant aramchol nash
Rheumatoid Arthritis Drugs Market to grow by USD 16.04 billion from 2023 to 2028; North America to account for 39% of market growth- Technavio
Published: 2023-12-04 (Crawled : 18:00) - prnewswire.com
ALPMF | News | $9.5 1.2K
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
GLAXF | News | $19.54 2.6K
|
Health Technology
|
| O: -2.6%
H: 1.1%
C: -1.18%
SNYNF | News | $94.25 480
|
Health Technology
|
| O: 0.27%
H: 0.12%
C: 0.12%
NVSEF | News | $96.0 52K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
ALPMY | News | $9.49 480K
|
Manufacturing
|
| O: 0.0%
H: 0.5%
C: 0.17%
NVS | News | $97.515 0.24% 820K
|
Health Technology
|
| O: -1.86%
H: 0.34%
C: -0.19%
GSK | News | $40.73 -1.24% 360K
|
Health Technology
|
| O: -1.01%
H: 0.39%
C: 0.19%
ABBV | News | $168.1 -0.85% 670K
|
Health Technology
|
| O: 0.51%
H: 0.68%
C: 0.32%
SNY | News | $46.82 -1.82% 510K
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
GLMD | $0.3614 11K
|
Health Technology
|
| O: 0.03%
H: 2.44%
C: -1.03%
AMGN | News | $273.6 0.02% 370K
|
Health Technology
|
| O: -0.25%
H: 0.05%
C: -0.37%
america market
Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
Published: 2023-11-20 (Crawled : 23:00) - biospace.com/
GLMD | $0.3614 11K
|
Health Technology
|
| O: -0.52%
H: 7.23%
C: 7.23%
study
Global NASH Market to Soar to $2.71 Billion by 2023, Driven by Rising Prevalence of Silent Liver Disease
Published: 2023-11-11 (Crawled : 04:20) - prnewswire.com
AZN | News | $70.93 0.11% 2.3M
|
Health Technology
| Email alert
Add to watchlist
GALT | $3.435 1.63% 18K
|
Health Technology
| Email alert
Add to watchlist
GLMD | $0.3614 11K
|
Health Technology
| Email alert
Add to watchlist
GNFT | $3.4449 1.4K
|
Health Technology
| Email alert
Add to watchlist
ICPT | $19.0 -0.05% 4M
|
Health Technology
| Email alert
Add to watchlist
IVA | $3.12 -5.17% 9.8K
|
Health Technology
| Email alert
Add to watchlist
MDGL | $215.21 -1.45% 52K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $97.515 0.24% 820K
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $96.0 52K
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $140.3 1.5K
|
Health Technology
| Email alert
Add to watchlist
IVEVF | $3.73 0% 1K
|
n/a
| Email alert
Add to watchlist
liver disease global nash market
Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis
Published: 2023-09-26 (Crawled : 14:30) - biospace.com/
GLMD | $0.3614 11K
|
Health Technology
|
| O: -2.0%
H: 5.0%
C: -0.66%
patent treatment fibrosis aramchol
Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
Published: 2023-09-22 (Crawled : 20:00) - prnewswire.com
GLMD | $0.3614 11K
|
Health Technology
| Email alert
Add to watchlist
nasdaq pharmaceuticals
Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering
Published: 2023-07-14 (Crawled : 15:00) - biospace.com/
GLMD | $0.3614 11K
|
Health Technology
|
| O: 1.92%
H: 0.0%
C: -31.6%
offering pharmaceuticals
Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC
Published: 2023-07-10 (Crawled : 14:00) - biospace.com/
GLMD | $0.3614 11K
|
Health Technology
|
| O: 9.43%
H: 0.0%
C: -13.1%
trial
Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments
Published: 2023-06-01 (Crawled : 18:00) - biospace.com/
GLMD | $0.3614 11K
|
Health Technology
|
| O: 0.0%
H: 6.94%
C: 0.43%
pharmaceuticals financial results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 59% | 41% |
Top 10 Gainers
CSSE 4 | $0.3686 142.02% 76M
|
Consumer Services
CZOO | $11.685 134.17% 7.6M
|
BOF | $1.93 64.96% 55M
|
AMST | $3.14 57.0% 59M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
WHLM | $6.61 30.12% 400K
|
Commercial Services
RILY | $27.91 28.5% 8.9M
|
Finance
RBBN 4 | $3.25 26.46% 1.5M
|
Electronic Technology
Last 48 Hours Insiders Buying
TPL P 3 | $585.24 -0.44% 8K
|
Miscellaneous
|
15:01
ISBA P 966 | $18.0001 3.1K
|
Finance and Insurance
|
15:01
MEGI | $11.97 -0.08% 42K
|
|
00:30
CTRN P 29000 | $22.445 0.97% 16K
|
Retail Trade
|
22:00
CONN | $3.75 1.35% 19K
|
Retail Trade
|
21:30
TGEN P 6000 | $0.685 6.6K
|
Utilities
|
18:30
CMTV P 700 | $16.59 1K
|
Finance and Insurance
|
18:30
FNB | $13.565 -0.48% 210K
|
Finance
|
17:30
RMCF | $3.54 410
|
Consumer Non-Durables
|
20:10